Hematopoietic stem cell transplantation activity in Mexico during the COVID19 pandemic: on the way to recovery

References

• Leon Rodriguez E, Rivera Franco MM. Outcomes of hematopoietic stem cell transplantation at a limited-resource center in Mexico Are comparable to those in developed countries. Biol Blood Marrow Transplant. 2017;23(11):1998–2003. doi:10.1016/j.bbmt.2017.07.010.
   PubMed Web of Science ®Google Scholar
• Saito AM, Cutler C, Zahrieh D, et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008;14(2):197–207. doi:10.1016/j.bbmt.2007.10.010.
   PubMed Web of Science ®Google Scholar
• Barr RD. The importance of lowering the costs of stem cell transplantation in developing countries. Int J Hematol 2002;76(1):365–367. doi:10.1007/BF03165286
   PubMedGoogle Scholar
• Mahmoudjafari Z, Alexander M, Roddy J, et al. American society for transplantation and cellular therapy pharmacy special interest group position statement on pharmacy practice management and clinical management for COVID-19 in hematopoietic cell transplantation and cellular therapy patients in the United States. Biol Blood Marrow Transplant. 2020;26(6):1043–1049. doi:10.1016/j.bbmt.2020.04.005.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan VS, Nair R, Goel G, et al. COVID-19 and haematology services in a cancer centre from a middle-income country: adapting service delivery, balancing the known and unknown during the pandemic. Ecancermedicalscience. 2020;14:1110. doi:10.3332/ecancer.2020.1110.
   PubMed Web of Science ®Google Scholar
• Mengling T, Rall G, Bernas SN, et al. Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS. Bone Marrow Transplant 2021;56(4):798–806. doi:10.1038/s41409-020-01138-0.
   PubMed Web of Science ®Google Scholar
• Del Campo L, Ramírez López P, de la Cruz Benito A, et al. Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid. Expert Rev Hematol. 2021;14(1):1–5.
   Web of Science ®Google Scholar
• Colunga-Pedraza PR, Colunga-Pedraza JE, Meléndez-Flores JD, et al. Outpatient transplantation in the COVID-19 era: a single-center latin American experience. Bone Marrow Transplant 2021: 1–4. doi:10.1038/s41409-021-01360-4.
   Web of Science ®Google Scholar
• Rocha V, Fatobene G, Niederwieser D. & Increasing access to allogeneic hematopoietic cell transplant: an international perspective, Increasing access to allogeneic hematopoietic cell transplant: an international perspective. Hematology. 2021;2021:264–274. doi:10.1182/hematology.2021000258.
   PubMedGoogle Scholar
• Correa C, Gonzalez-Ramella O, Baldomero H, et al. Increasing access to hematopoietic cell transplantation in Latin America: results of the 2018 LABMT activity survey and trends since 2012 (2022). Bone Marrow transplant. 2018 LABMT activity survey and trends since 2012. Bone Marrow Transplant. Advance online publication. doi:10.1038/s41409-022-01630-9
   Google Scholar
• European Society for Blood and Marrow Transplantation. (2021). FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing, and Administration. Eight edition 8.1. https://www.ebmt.org/8th-edition-fact-jacie-standards.
   Google Scholar
• Ibarra-Nava I, la Garza C-d, Ruiz-Lozano JA, et al. Mexico and the COVID-19 response. Disaster Med Public Health Prep. 2020;14(4):e17–e18. doi:10.1017/dmp.2020.260.
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Chabannon C, et al. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey (2022). Bone Marrow transplant.−57 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplant; 57(5):742–752. doi:10.1038/s41409-022-01604-x.
   PubMed Web of Science ®Google Scholar
• Maurer K, Saucier A, Kim HT, et al. COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Advances. 2021;5(3):861–871. doi:10.1182/bloodadvances.2020003883.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan VS, Nair R, Goel G, et al. COVID-19 and haematology services in a cancer centre from a middle-income country: adapting service delivery, balancing the known and unknown during the pandemic. Ecancermedicalscience. 2020;14:1110. doi:10.3332/ecancer.2020.1110.
   PubMed Web of Science ®Google Scholar
• Doná D, Torres Canizales J, Benetti E, ERN TransplantChild et al. Pediatric transplantation in Europe during the COVID-19 pandemic: early impact on activity and healthcare. Clin Transplant. 2020;34(10):e14063. doi:10.1111/ctr.14063.
   PubMed Web of Science ®Google Scholar
• Russo D, Polverelli N, Malagola M, GITMO Centers et al. Changes in stem cell transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian bone marrow transplant group (GITMO) nationwide analysis (TransCOVID-19 survey). Bone Marrow Transplant 2021;56(9):2272–2275. doi:10.1038/s41409-021-01287-w.
   PubMed Web of Science ®Google Scholar
• Be the Match Mexico. https://bethematch.org.mx. Accessed: May 03, 2022.
   Google Scholar
• Vasquez L, Sampor C, Villanueva G, et al. Early impact of the COVID-19 pandemic on paediatric cancer care in Latin America. Lancet Oncol. 2020;21(6):753–755. doi:10.1016/S1470-2045(20)30280-1.
   PubMed Web of Science ®Google Scholar
• Enujioke SC, McBrayer K, Soe KC, et al. Impact of COVID-19 on post graduate medical education and training. BMC Med Educ. 2021;21(1):580. doi:10.1186/s12909-021-03019-6.
   PubMed Web of Science ®Google Scholar
• Shah AC, O'Dwyer LC, Badawy SM. Telemedicine in malignant and nonmalignant hematology: systematic review of pediatric and adult studies. JMIR Mhealth Uhealth. 2021 Jul;9(7):e29619. doi:10.2196/29619. PMID: 34255706; PMCID: PMC8299344.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Mikulska M, de la Camara R, et al. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow transplant.−55 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplant. 2020;55(11):2071–2076. doi:10.1038/s41409-020-0919-0.
   PubMed Web of Science ®Google Scholar
• FOUNDATION FOR THE ACCREDITATION OF CELLULAR THERAPY, JOINT ACCREDITATION COMMITTEE ISCT and EBMT (JACIE). FACT-JACIE International Standards for HEMATOPOIETIC CELLULAR THERAPY Product Collection, Processing, and Administration [Internet]. 2021 dic. Available at: https://www.ebmt.org/8th-edition-fact-jacie-standards
   Google Scholar
• Das M. Shortage of cancer drugs in Mexico. Lancet Oncol. 2021;22(9):1216), doi:10.1016/S1470-2045(21)00452-6.
   PubMed Web of Science ®Google Scholar